• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Quince Therapeutics, Inc. - Common Stock (NQ:QNCX)

    3.565 +0.685 (+23.78%)
    Streaming Delayed Price Updated: 1:40 PM EST, Jan 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,093,830
    Open 2.950
    Bid (Size) 3.560 (100)
    Ask (Size) 3.570 (300)
    Prev. Close 2.880
    Today's Range 2.950 - 3.600
    52wk Range 0.7203 - 4.550
    Shares Outstanding 36,382,989
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
    From Quince Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +18.8%
    +18.8%
    1 Month
    -3.6%
    -3.6%
    3 Month
    +84.7%
    +84.7%
    6 Month
    +94.8%
    +94.8%
    1 Year
    +102.6%
    +102.6%

    More News

    Read More
    News headline image
    Wednesday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Which stocks are moving on Wednesday? ↗
    Via Chartmill
    News headline image
    Quince Therapeutics to Participate at Investor Events in December 2025
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    This Lionsgate Studios Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
    Via Benzinga
    News headline image
    Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Top movers in Wednesday's after hours session ↗
    Via Chartmill
    News headline image
    Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
    From Quince Therapeutics, Inc.
    Via Business Wire
    News headline image
    Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Quince Therapeutics to Present at Citizens Life Sciences Conference
    From Quince Therapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Quince Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Quince Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Quince Therapeutics, Inc. - Common Stock trade on?
    Quince Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Quince Therapeutics, Inc. - Common Stock?
    The ticker symbol for Quince Therapeutics, Inc. - Common Stock is QNCX on the Nasdaq Stock Market
    What is the current price of Quince Therapeutics, Inc. - Common Stock?
    The current price of Quince Therapeutics, Inc. - Common Stock is 3.565
    When was Quince Therapeutics, Inc. - Common Stock last traded?
    The last trade of Quince Therapeutics, Inc. - Common Stock was at 01/16/26 01:40 PM ET
    What is the market capitalization of Quince Therapeutics, Inc. - Common Stock?
    The market capitalization of Quince Therapeutics, Inc. - Common Stock is 129.71M
    How many shares of Quince Therapeutics, Inc. - Common Stock are outstanding?
    Quince Therapeutics, Inc. - Common Stock has 130M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.